Shawn Marshall Rose - 23 Jun 2025 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role: Chief Medical Officer, Head of Research & Development
Signature: /s/ Bridgette Housley, as Attorney-in-Fact
Issuer symbol: NKTX
Transactions as of: 23 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 25 Jun 2025, 16:00:06 UTC
Next filing: 08 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rose Shawn Marshall	Chief Medical Officer, Head of Research & Development	1150 VETERANS BLVD, SOUTH SAN FRANCISCO	/s/ Bridgette Housley, as Attorney-in-Fact	25 Jun 2025	0002073530

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NKTX	Stock Option (right to buy)	Award	$0	+500,000		$0.000000	500,000	23 Jun 2025	Common Stock	500,000	$1.75	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option is scheduled to vest and become exercisable as to 25% of the shares subject to the grant on July 23, 2026. The remaining portion of the option is scheduled to vest and become exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 23, 2026.

Remarks:

Chief Medical Officer, Head of Research & Development